Mosunetuzumab
- Generic Name
- Mosunetuzumab
- Brand Names
- Lunsumio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1905409-39-3
- Unique Ingredient Identifier
- LDJ89SS0YG
- Background
Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as rituximab, in co...
- Indication
Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
- Associated Conditions
- Relapsed or Refractory Follicular Lymphoma
- Associated Therapies
- -
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT05886036
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05849857
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇫🇮Helsinki University Hospital, Helsinki, Finland
🇳🇴St. Olavs hospital, Trondheim, Norway
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Biological: Axicabtagene CiloleucelProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideBiological: MosunetuzumabOther: Patient ObservationDrug: FludarabineDrug: Polatuzumab VedotinBiological: Lisocabtagene MaraleucelProcedure: Positron Emission TomographyBiological: Tisagenlecleucel
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 396
- Registration Number
- NCT05633615
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05615636
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT05464329
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT05412290
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 34
- Registration Number
- NCT05410418
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Mosunetuzumab in People With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT05389293
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, New Jersey, United States
🇺🇸Georgetown University (Data Collection Only), Washington, District of Columbia, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Lazaros Lekakis
- Target Recruit Count
- 22
- Registration Number
- NCT05260957
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.